↓ Skip to main content

Cochrane Database of Systematic Reviews

Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood

Overview of attention for article published in Cochrane database of systematic reviews, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
33 tweeters
facebook
2 Facebook pages
wikipedia
1 Wikipedia page
video
1 video uploader

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
309 Mendeley
Title
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Published in
Cochrane database of systematic reviews, February 2016
DOI 10.1002/14651858.cd007786.pub3
Pubmed ID
Authors

Robert S Phillips, Amanda J Friend, Faith Gibson, Elizabeth Houghton, Shireen Gopaul, Jean V Craig, Barry Pizer

Abstract

Nausea and vomiting remain a problem for children undergoing treatment for malignancies despite new antiemetic therapies. Optimising antiemetic regimens could improve quality of life by reducing nausea, vomiting, and associated clinical problems. This is an update of the original systematic review. To assess the effectiveness and adverse events of pharmacological interventions in controlling anticipatory, acute, and delayed nausea and vomiting in children and young people (aged less than 18 years) about to receive or receiving chemotherapy. Searches included the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, PsycINFO, conference proceedings of the American Society of Clinical Oncology, International Society of Paediatric Oncology, Multinational Association of Supportive Care in Cancer, and ISI Science and Technology Proceedings Index from incept to December 16, 2014, and trial registries from their earliest records to December 2014. We examined references of systematic reviews and contacted trialists for information on further studies. We also screened the reference lists of included studies. Two review authors independently screened abstracts in order to identify randomised controlled trials (RCTs) that compared a pharmacological antiemetic, cannabinoid, or benzodiazepine with placebo or any alternative active intervention in children and young people (less than 18 years) with a diagnosis of cancer who were to receive chemotherapy. Two review authors independently extracted outcome and quality data from each RCT. When appropriate, we undertook meta-analysis. We included 34 studies that examined a range of different antiemetics, used different doses and comparators, and reported a variety of outcomes. The quality and quantity of included studies limited the exploration of heterogeneity to narrative approaches only.The majority of quantitative data related to the complete control of acute vomiting (27 studies). Adverse events were reported in 29 studies and nausea outcomes in 16 studies.Two studies assessed the addition of dexamethasone to 5-HT3 antagonists for complete control of vomiting (pooled risk ratio (RR) 2.03; 95% confidence interval (CI) 1.35 to 3.04). Three studies compared granisetron 20 mcg/kg with 40 mcg/kg for complete control of vomiting (pooled RR 0.93; 95% CI 0.80 to 1.07). Three studies compared granisetron with ondansetron for complete control of acute nausea (pooled RR 1.05; 95% CI 0.94 to 1.17; 2 studies), acute vomiting (pooled RR 2.26; 95% CI 2.04 to 2.51; 3 studies), delayed nausea (pooled RR 1.13; 95% CI 0.93 to 1.38; 2 studies), and delayed vomiting (pooled RR 1.13; 95% CI 0.98 to 1.29; 2 studies). No other pooled analyses were possible.Narrative synthesis suggests that 5-HT3 antagonists are more effective than older antiemetic agents, even when these agents are combined with a steroid. Cannabinoids are probably effective but produce frequent side effects. Our overall knowledge of the most effective antiemetics to prevent chemotherapy-induced nausea and vomiting in childhood is incomplete. Future research should be undertaken in consultation with children, young people, and families that have experienced chemotherapy and should make use of validated, age-appropriate measures. This review suggests that 5-HT3 antagonists are effective in patients who are to receive emetogenic chemotherapy, with granisetron or palonosetron possibly better than ondansetron. Adding dexamethasone improves control of vomiting, although the risk-benefit profile of adjunctive steroid remains uncertain.

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 309 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 <1%
Colombia 1 <1%
South Africa 1 <1%
Unknown 306 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 58 19%
Student > Bachelor 44 14%
Researcher 25 8%
Student > Ph. D. Student 23 7%
Other 22 7%
Other 56 18%
Unknown 81 26%
Readers by discipline Count As %
Medicine and Dentistry 96 31%
Nursing and Health Professions 50 16%
Pharmacology, Toxicology and Pharmaceutical Science 17 6%
Psychology 15 5%
Agricultural and Biological Sciences 10 3%
Other 33 11%
Unknown 88 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2017.
All research outputs
#1,330,350
of 22,120,510 outputs
Outputs from Cochrane database of systematic reviews
#3,098
of 12,187 outputs
Outputs of similar age
#25,947
of 378,639 outputs
Outputs of similar age from Cochrane database of systematic reviews
#57
of 195 outputs
Altmetric has tracked 22,120,510 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,187 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.9. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,639 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 195 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.